血清肿瘤标志物检测对晚期非小细胞肺癌靶向治疗的预后分析

目的：探究检测血清肿瘤标志物对预测晚期非小细胞肺癌靶向治疗预后的影响。方法：选取2010年4月至2012年12我院收治的晚期非小细胞肺癌患者70例，均予以吉非替尼进行治疗，检测治疗前及治疗后2个月肿瘤标志物癌胚抗原CEA、角蛋白19的可溶性片段（CYFRA21—1）、癌抗原125（CA125）的表达水平，观察其表达水平与患者疗效之间的关系。结果：治疗后，患者完全缓解1例，部分缓解37例，疾病稳定19例，疾病进展13例，有效率为54．3％。治疗后，治疗有效的患者CEA、CA125明显比治疗前降低，结果具有统计学意义（P〈0．05）；而疾病稳定、疾病进展的患者治疗后CEA、CA125与治疗前比却无明显差异（P〉0．05）。治疗有效与疾病稳定的患者治疗后CYFRA21．1有明显降低，但与治疗前比却无明显差异（P〉0．05）；而疾病进展患者的CYFRA21—1却明显升高，与治疗前比有显著差异（P〈0．05）。而治疗前，治疗有效的患者血清中CEA、CA125比疾病稳定、疾病进展的患者明显较高，结果具有统计学意义（P〈0．05）；疾病稳定患者的CEA、CA125与疾病进展患者的相比，治疗有效的患者CYFRA21-1与疾病稳定、疾病进展的相比，结果均不具有统计学意义（P〉0．05）。结论：治疗前CEA、CA125浓度较高则治疗效果不错．治疗后效果较好则CEA、CA125浓度较低，效果不好则CYFRA21-1浓度较高。利用血清肿瘤标志物可显著反映肿瘤靶向药物治疗的预后情况，为临床判断其治疗效果提供依据。

Clinical Analysis of Detecting Serum Tumor Markers in the Prognosis of Advanced Non-Small Cell Lung Cancer Targeted Therapy

Objective： To explore detecting serum tumor markers to predict the prognosis of advanced non-small cell hmg cancer targeted therapy. Methods： Selected 70 cases NSCLCs patients accepted by our hospital from April 2010 to December 2012. All the patients were taken Iressa to treat. And the tumor markers were detected before treatment and two months after treatment, included antigen （CEA）, soluble fragment of cytokeratin 19 （CYFRA21-1） and cancer antigen 125 （CA125）. The relationship between the expression levels and efficacy in patients were observed. Results： After treatment, there were one case of patients with complete remission（CR）, 37 cases with partial remission（PR）, stable disease（SD）, 13 cases with progression disease（PD）, and the effective rate was 54.3%. And after treatment, effective treatment （ET） with CEA and CA125 were significantly lower than before treatment, the results were statistically significant （P 〈0.05）; but CEA and CA125 were with no significant difference （17〉0.05） between SD and PD. The CYFRA21-1 in ET and SD were with no significant difference （P〉0.05） compared with pre-treatment, but in PD was significantly increased. Before treatment, CEA and CA125 in ET were significantly higher than SD and PD （P〈0.05）. But CEA and CA125 in SD compared with PD, CYFRA21-1 in ET compared with SD and PD, were with no significant difference （P〉0.05）. Conclusion： The higher of the concentration of CEA and CA125 before treatment, the better are the efficacy. The concentration of CEA and CA125 are lower after treatment will get better efficacy, and the CYFRA21-1 are higher will get worse efficacy. The use of serum tumor markers can significantly reflect the targeted cancer drug treatment prognosis, which will provide a basis for its therapeutic effect for clinical judgment.